Kodiak Sciences Inc (KOD)
3.29
-0.45
(-12.03%)
USD |
NASDAQ |
May 17, 16:00
3.29
0.00 (0.00%)
After-Hours: 20:00
Kodiak Sciences Research and Development Expense (Quarterly): 29.93M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 29.93M |
| December 31, 2023 | 46.63M |
| September 30, 2023 | 36.19M |
| June 30, 2023 | 66.96M |
| March 31, 2023 | 56.52M |
| December 31, 2022 | 55.99M |
| September 30, 2022 | 61.68M |
| June 30, 2022 | 73.74M |
| March 31, 2022 | 76.18M |
| December 31, 2021 | 75.60M |
| September 30, 2021 | 56.00M |
| June 30, 2021 | 45.40M |
| March 31, 2021 | 40.34M |
| December 31, 2020 | 37.36M |
| Date | Value |
|---|---|
| September 30, 2020 | 29.31M |
| June 30, 2020 | 20.56M |
| March 31, 2020 | 20.17M |
| December 31, 2019 | 12.83M |
| September 30, 2019 | 10.12M |
| June 30, 2019 | 8.838M |
| March 31, 2019 | 5.723M |
| December 31, 2018 | 6.851M |
| September 30, 2018 | 4.709M |
| June 30, 2018 | 3.591M |
| March 31, 2018 | 3.642M |
| December 31, 2017 | 8.776M |
| September 30, 2017 | 3.148M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.838M
Minimum
Jun 2019
76.18M
Maximum
Mar 2022
43.02M
Average
42.87M
Median
Research and Development Expense (Quarterly) Benchmarks
| Avalo Therapeutics Inc | 2.116M |
| Regeneron Pharmaceuticals Inc | 1.248B |
| Ligand Pharmaceuticals Inc | 5.971M |
| iBio Inc | 1.535M |
| Dare Bioscience Inc | 3.328M |